person · Reporting owner
Scheessele William John
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Chief Commercial Officer | April 14, 2025 | April 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date April 14, 2025 · Filed April 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,018 |
Reported balance
After 2025-04-14 transaction · row 1
1 source rowRow 1 · 2025-04-14 · Purchase · Acquired 6,493 · Balance 22,018 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2025 Filed Apr 15, 2025 16:03 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 6,493 | $1.54 | $9,999.22 |
DisclosureSEC source: 0001818382-25-000052 · wk-form4_1744747408.xml · nonDerivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,018 Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:34 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 283,101 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001818382-25-000020 · wk-form4_1737668091.xml · derivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,101 Underlying: Common Stock · 283,101 shares Expires 2035-01-21 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 276,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001818382-23-000197 · wk-form4_1702415423.xml · derivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,000 Underlying: Common Stock · 276,000 shares Expires 2033-12-08 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 19:53 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 5,000 | $3.09 | $15,450.00 |
DisclosureSEC source: 0001818382-22-000212 · wf-form4_167115202101303.xml · nonDerivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,525 Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 16:15 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 136,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001818382-22-000201 · wf-form4_167087968780298.xml · derivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2032-12-08 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026. Read SEC document |
| May 24, 2022 Filed May 25, 2022 11:46 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 10,525 | $4.72 | $49,678.00 |
DisclosureSEC source: 0001818382-22-000053 · wf-form4_165349360232953.xml · nonDerivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,525 Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:51 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 157,558 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126728 · tm2130120-7_4seq1.xml · derivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,558 Underlying: Common Stock · 157,558 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on August 9, 2022, after which 1/36 of the option will become exercisable on the 9th of each month through August 9, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.